Coronary artery diseaseComparison of In-Hospital Mortality from Acute Myocardial Infarction in HIV Sero-Positive Versus Sero-Negative Individuals
Section snippets
Methods
Data were obtained from the Nationwide Inpatient Sample (NIS), developed as part of the Healthcare Cost and Utilization Project, a federal-state-industry partnership sponsored by the Agency for Healthcare Research and Quality. The NIS is designed to approximate a stratified 20% sample of all nonfederal, short-term, general, and specialty hospitals serving adults in the United States. The sampling strategy selects hospitals nationwide from the state inpatient database according to defined strata
Results
The frequency and distribution of all study variables are listed in Table 1. The results demonstrate that most in-hospital encounters for AMI were in patients aged ≥55 years who were white, male, and privately insured. Most AMI encounters occurred in patients with CCI scores ≤2, and the mean length of hospital stay was 5.29 days (SE 0.03). The most common medical co-morbidities for patients with AMI were hypertension (51.0%), diabetes without complications (23.6%), congestive heart failure
Discussion
Our study demonstrates that the relative in-hospital mortality risk from an AMI event was significantly higher for seropositive compared to seronegative patients. This risk remained significantly higher even after accounting for the influence of demographics, medical co-morbidities, hospital type, dyslipidemia, and number of in-hospital procedures. Although it is difficult to determine the causes for the observed disproportionate mortality outcome, an underlying increased co-morbidity burden,
References (28)
- et al.
Validation of a combined comorbidity index
J Clin Epidemiol
(1994) - et al.
Coronary artery lesions and human immunodeficiency virus infection
Res Virol
(1993) - et al.
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
Lancet
(1999) - et al.
Heart Disease and Stroke Mortality in the 20th Century
(2006) - et al.
Deaths: injuries 2002
Natl Vital Stat Rep
(2006) - et al.
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
Lancet
(2006) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study
AIDS
(2010)- et al.
Arteriopathy in children with acquired immune deficiency syndrome
Pediatr Pathol
(1987) - et al.
Interleukin-18: a proinflammatory cytokine in HIV-1 infection
Curr HIV Res
(2006) Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP)
(1997-2006)
Age- and sex-specific in-hospital mortality after myocardial infarction in routine clinical practice
Cardiol Res Pract
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Med Care
Morbidity and mortality in HIV-infected individuals—a shift towards comorbidities
Swiss Med Wkly
Acute myocardial infarction in human immunodeficiency virus-infected patients
Arch Intern Med
Cited by (41)
Coronary revascularization in patients with HIV
2022, Trends in Cardiovascular MedicineCitation Excerpt :People living with HIV (PLWH) are now more likely to die from cardiovascular diseases due to a high incidence of traditional cardiovascular risk factors, persistent HIV-related inflammation and side-effects of long-term cART [2]. HIV increases the overall risk for developing cardiovascular disease by 1.5–2.0-fold and the risk for sudden cardiac death by 4.5-fold [2–4]. An expanding population of PLWH with coronary artery disease (CAD) means that healthcare practitioners will more frequently be faced with HIV patients requiring coronary revascularization in the form of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
HIV and cardiovascular disease
2020, The Lancet HIVEvaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study
2018, AtherosclerosisCitation Excerpt :Recently, a role of the gut microbiota has been highlighted, [31–33] while it is still not clear if a lower CD4 cell count is associated with a higher cardiovascular risk [34–37]. In the setting of ACS, HIV patients are usually younger, smokers, predominantly males, with an age of onset <50 years [38], but with a higher risk of cardiovascular complications and sudden cardiac death [39]. In this setting, there is lack of data about coronary disease features of HIV patients presenting with acute coronary syndrome, and their potential impact on prognosis.
Cardiovascular disease in women living with HIV: A narrative review
2018, MaturitasCitation Excerpt :The association between HIV and CVD has long been documented, with studies reporting a 1.5–2.0-fold increase in the risk in PLWH, even in the context of virological suppression [4,5]. Furthermore, there is evidence to suggest that intervention rates in acute myocardial infarction are lower in those living with HIV when compared with their seronegative counterparts, and that mortality is higher [6]. The pathophysiology of CVD in HIV is complex, and is driven by a number of factors.
HIV and coronary disease – When secondary prevention is insufficient
2017, Revista Portuguesa de CardiologiaHIV and Ischemic Heart Disease
2017, Journal of the American College of CardiologyCitation Excerpt :With regard to CVD outcomes, HIV-positive patients also have a greater risk of developing cardiovascular complications (4). Data from the Nationwide Inpatient Sample in the United States demonstrated that HIV-positive patients with myocardial infarction (MI) have lower MI-related intervention rates and higher death rates compared with their seronegative counterparts (23). They also have a 4.5-fold increased rate of sudden cardiac death, which has been associated with a history of previous MI, cardiomyopathy, heart failure, arrhythmia, hypertension, and dyslipidemia (24).